Stocks in play: Cipher Pharmaceuticals Inc.
Announces the signing of a definitive asset purchase agreement with ParaPRO LLC and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total consideration of US$89.5 million. Cipher Pharmaceuticals Inc. shares T.CPH are trading up $1.93 at $10.61.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.